<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1772">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318015</url>
  </required_header>
  <id_info>
    <org_study_id>ProfilaxisCOVID</org_study_id>
    <nct_id>NCT04318015</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)</brief_title>
  <acronym>PHYDRA</acronym>
  <official_title>Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Respiratory Diseases, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Respiratory Diseases, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triple blinded, phase III randomized controlled trial with parallel groups (200mg of
      hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and
      efficacy as prophylaxis treatment for healthcare personnel exposed to COVID-19 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthcare personnel infection with COVID-19 is a major setback in epidemiological
      emergencies. Hydroxychloroquine has proven to inhibit coronavirus in-vitro but no data to
      date has proven in-vivo effects. Nevertheless, hydroxychloroquine is a low cost, limited
      toxicity and broadly used agent. Since there is currently no treatment for COVID-19 exposure
      prophylaxis, the investigators will implement a triple blinded, phase III randomized
      controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) for
      60 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Triple blinded, randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization will happen after previous assignment of recruited individual to high-risk or low-risk exposure according to he or her activities. An independent member of the team will randomly assign treatment or placebo following a computer based program. Blinding will end in case elimination criteria are met.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic COVID-19 infection rate</measure>
    <time_frame>From date of randomization until the appearance of symptoms or study completion 60 days after treatment start</time_frame>
    <description>Symptomatic infection rate by COVID-19 defined as cough, dyspnea, fever, myalgia, arthralgias or rhinorrhea along with a positive COVID-19 real-time polymerase chain reaction test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic non-COVID viral infection rate</measure>
    <time_frame>From date of randomization until the appearance of symptoms or study completion 60 days after treatment start</time_frame>
    <description>Symptomatic infection rate by other non-COVID-19 viral etiologies defined as cough, dyspnea, fever, myalgia, arthralgias or rhinorrhea along with a positive viral real time polymerase chain reaction test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of labor absenteeism</measure>
    <time_frame>From date of randomization until study completion 60 days after treatment start</time_frame>
    <description>Number of days absent from labor due to COVID-19 symptomatic infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of labor absenteeism</measure>
    <time_frame>From date of randomization until study completion 60 days after treatment start</time_frame>
    <description>Absenteeism from labor rate due to COVID-19 symptomatic infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of severe respiratory COVID-19 disease in healthcare personnel</measure>
    <time_frame>From date of randomization until the appearance of symptoms or study completion 60 days after treatment start</time_frame>
    <description>Rate of severe respiratory COVID-19 disease in healthcare personnel</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <arm_group>
    <arm_group_label>High-risk Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine 200mg per day for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-risk Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet per day for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-risk Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine 200mg per day for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-risk Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet per day for 60 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>All treatment will be administered orally.</description>
    <arm_group_label>High-risk Treatment</arm_group_label>
    <arm_group_label>Low-risk Treatment</arm_group_label>
    <other_name>Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>All placebo will be administered orally</description>
    <arm_group_label>High-risk Placebo</arm_group_label>
    <arm_group_label>Low-risk Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old upon study start

          -  Healthcare personnel exposed to patients with COVID-19 respiratory disease:
             physicians, nurses, chemists, pharmacists, janitors, stretcher-bearer, administrative
             and respiratory therapists.

          -  Signed consent for randomization to any study arm.

        Exclusion Criteria:

          -  Known hypersensitivity to hydroxychloroquine manifested as anaphylaxis

          -  Current treatment to chloroquine or hydroxychloroquine

          -  Women with last menstruation date farther than a month without negative pregnancy
             test.

          -  Women with positive pregnancy test

          -  Breastfeeding women

          -  Chronic hepatic disease history (Child-Pugh B or C)

          -  Chronic renal disease (GFR less or equal to 30)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Rojas-Serrano, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rogelio Perez-Padilla, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Jurado-Camacho, MD. MSc</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ireri Thirion-Romero, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastian Rodríguez-Llamazares, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Hernandez Cárdenas, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristobal Guadarrama-Pérez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandra Ramírez-Venegas, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Respiratory Diseases - México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe Camacho-Jurado, MD</last_name>
    <phone>+52 55871700</phone>
    <phone_ext>5305</phone_ext>
    <email>lfjcamacho@comunidad.unam.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rogelio Perez-Padilla, MD. PhD.</last_name>
    <phone>+52 55871700</phone>
    <phone_ext>5305</phone_ext>
    <email>perezpad@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias, &quot;Ismael Cosío Villegas&quot;</name>
      <address>
        <city>Mexico, City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aranxta Remigio, MD</last_name>
      <phone>+52 5532 590125</phone>
      <email>iner.hydra@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rogelio Perez Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>April 15, 2020</last_update_submitted>
  <last_update_submitted_qc>April 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

